Airway Management in Massive CNS Depressant Overdose

Immediate Airway Protection

The American Heart Association (AHA) recommends that the most critical step to prevent aspiration in a massive mixed CNS‑depressant overdose is immediate endotracheal intubation to secure the airway and protect against loss of protective reflexes. 1
Endotracheal intubation is the definitive intervention when loss of gag and cough reflexes—rather than complete respiratory arrest—is the primary mechanism leading to aspiration risk. 2

Pre‑oxygenation: Deliver 100 % oxygen before induction to maximize oxygen reserves. 3
Cricoid pressure: Apply 10 N (≈1 kg) while the patient is awake, increasing to 30 N (≈3 kg) after loss of consciousness to reduce the risk of passive regurgitation. 3
Suction: Remove oropharyngeal secretions under direct vision prior to laryngoscopy. 4
Patient positioning: Use a head‑elevated (ramped) position when hemodynamically stable to improve glottic view and reduce aspiration risk. 5

Videolaryngoscopy: Prefer video‑assisted laryngoscopy when available to increase first‑pass success. 5
Neuromuscular blockade: Use rocuronium rather than succinylcholine in overdose patients to avoid potential hyperkalemia and prolonged apnea. 5
Cricoid pressure adjustment: Reduce or release cricoid pressure if it hinders laryngoscopic view or tube passage. 3
Tube confirmation: Verify endotracheal tube placement immediately with waveform capnography. 5

Positioning: Place the patient in the lateral decubitus (recovery) position to allow secretions to drain; avoid supine positioning. (Supported by AHA.) 1
Basic airway opening: Use jaw‑thrust or chin‑lift maneuvers to maintain an open airway. 1
Bag‑mask ventilation: Provide positive‑pressure ventilation with 100 % oxygen if needed. 2
Adjunct airways: Insert an oropharyngeal or nasopharyngeal airway if tolerated. 3
CPAP: Apply continuous positive airway pressure during bag‑mask ventilation to improve oxygenation and reduce aspiration risk. 5

Naloxone first: In mixed overdoses, administer naloxone before other antidotes because opioids cause markedly greater respiratory depression than benzodiazepines. 6

The AHA advises that flumazenil should not be used in undifferentiated or mixed overdoses because of safety concerns. Absolute contraindications include:
Flumazenil may fail to fully reverse respiratory depression in mixed overdoses and has a short duration of action (~1 hour) compared with prolonged benzodiazepine effects. 7

Do not delay intubation while attempting pharmacologic reversal when protective airway reflexes are absent. 1
Do not use flumazenil in undifferentiated/mixed overdoses; the 2010 AHA assigns a Class III (harm) recommendation to this practice. 2
Do not assume isolated benzodiazepine overdose; most massive CNS depressant overdoses involve multiple agents, especially opioids. 1
Do not withhold naloxone due to concerns about concurrent benzodiazepine ingestion; prompt naloxone administration is advised when opioid involvement is suspected. 6

Maintain mechanical ventilation with appropriate settings tailored to the patient’s physiology. 5
Continue 100 % oxygen initially, then titrate FiO₂ to achieve target SpO₂ levels. 5

Flumazenil should not be administered to patients with diphenhydramine overdose, particularly when benzodiazepine co‑ingestion is possible, because it is contraindicated in mixed overdoses and provides no therapeutic benefit for anticholinergic toxicity 10